AHA urges HHS to block Novo Nordisk's 340B data demand, citing legal and cost concerns for safety-net hospitals and covered entities.

AHA letter to the Health Resources and Services Administration about a new concerning development with the 340B Program.

The Health Resources and Services Administration Feb. 25 said it will extend the deadline to April 20 to receive comments on ...

This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...

Feds back AbbVie Colorado 340B fight, arguing state law conflicts with federal 340B program in a key 10th Circuit appeal.

The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful. The 340B program ...

The drug discount program is under scrutiny on a variety of fronts ...

On July 31, 2025, the Health Resources and Services Administration (“HRSA”) announced the availability of a voluntary 340B Rebate Model Pilot Program (the “340B Rebate Pilot” or the “Pilot”) that ...

On December 29, 2025, Chief Judge Lance Walker of the U.S. District Court for the District of Maine granted the plaintiffs’ motion for a preliminary injunction in American Hospital Association v.

The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program ...